Rain Oncology Inc. (NASDAQ:RAIN – Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 861,800 shares, a decline of 20.2% from the August 15th total of 1,080,000 shares. Approximately 4.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 472,700 shares, the short-interest ratio is presently 1.8 days.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the company. Oppenheimer cut Rain Oncology from an “outperform” rating to a “market perform” rating in a report on Monday, May 22nd. Lifesci Capital lowered shares of Rain Oncology from an “outperform” rating to a “market perform” rating in a report on Monday, May 22nd. Citigroup downgraded shares of Rain Oncology from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 23rd. SVB Leerink cut shares of Rain Oncology from an “outperform” rating to a “market perform” rating in a research note on Monday, May 22nd. Finally, Guggenheim lowered shares of Rain Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, May 22nd. Ten research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.00.
Institutional Trading of Rain Oncology
Rain Oncology Stock Down 7.7 %
NASDAQ:RAIN traded down $0.07 on Friday, reaching $0.82. The company’s stock had a trading volume of 339,419 shares, compared to its average volume of 148,268. Rain Oncology has a 12-month low of $0.82 and a 12-month high of $14.48. The stock has a 50 day moving average price of $1.14 and a 200 day moving average price of $4.07. The firm has a market cap of $29.90 million, a price-to-earnings ratio of -0.32 and a beta of 0.21.
Rain Oncology (NASDAQ:RAIN – Get Free Report) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.12). Equities research analysts expect that Rain Oncology will post -1.67 EPS for the current fiscal year.
Rain Oncology Company Profile
Rain Oncology Inc, a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53.
- Five stocks we like better than Rain Oncology
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- What is Put Option Volume?
- MarketBeat Week in Review – 9/11 – 9/15
- 3 Fintech Stocks With Good 2021 Prospects
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Rain Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rain Oncology and related companies with MarketBeat.com's FREE daily email newsletter.